Allianz Asset Management
LAB icon

Allianz Asset Management’s Standard BioTools LAB Stock Holding History

Allianz Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-426,200
Closed -$1.16M – 2199
2024
Q1 		$1.16M Buy
+426,200
New +$1.03M ﹤0.01% 1367
2019
Q4 		– Sell
-171,598
Closed -$794K – 2813
2019
Q3 		$794K Sell
171,598
-859,124
-83% -$6.77M ﹤0.01% 2210
2019
Q2 		$12.7M Buy
1,030,722
+612,774
+147% +$7.8M 0.01% 1059
2019
Q1 		$5.55M Buy
+417,948
New +$4.41M 0.01% 1407
2015
Q3 		– Sell
-258,400
Closed -$6.25M – 2374
2015
Q2 		$6.25M Buy
+258,400
New +$8.16M 0.01% 1302
2014
Q3 		– Sell
-118,292
Closed -$3.48M – 2348
2014
Q2 		$3.48M Sell
118,292
-72,153
-38% -$2.31M ﹤0.01% 1031
2014
Q1 		$8.32M Buy
+190,445
New +$8.38M 0.01% 803

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Allianz Asset Management's LAB Position: Q2 2024 in Review

Allianz Asset Management sold out of Standard BioTools (LAB) in Q2 2024, closing a stake of 426,200 shares — an estimated $1.16M sold.

Allianz Asset Management first reported a position in LAB in Q1 2014 and held it in 7 quarters. The position peaked at $12.7M in Q2 2019. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2024.

  • Allianz Asset Management reported no remaining Standard BioTools position as of Q2 2024 after selling out during the quarter.
  • Allianz Asset Management sold 426,200 Standard BioTools shares in Q2 2024, an estimated $1.16M.
  • Allianz Asset Management first reported a position in Standard BioTools in Q1 2014 and held it in 7 quarters.
  • Allianz Asset Management's Standard BioTools position peaked at $12.7M in Q2 2019.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2024.

Based on Allianz Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.